A new US Food and Drug Administration draft guidance aims to lay out an efficient route by which biosimilar product sponsors can add new or previously protected reference product indications to their labeling.
Biosimilar and interchangeable product sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?